Peptide Dosages

GHRP-2 (5mg Vial) Dosage Protocol

Contents

Quickstart Highlights

GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic hexapeptide that stimulates potent, dose-dependent growth hormone release by activating ghrelin receptors[1]. Clinical studies predominantly employ once-daily subcutaneous administration to elicit robust pulsatile GH release while minimizing receptor desensitization[2][3]. This educational protocol presents a practical gradual titration approach with clear insulin-syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
  • Typical daily range: 100–300 mcg once daily subcutaneously.
  • Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).
GHRP-2 (5mg Vial)
📘 Important: Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 100 mcg 6 units (0.06 mL)
Weeks 3–4 150 mcg 9 units (0.09 mL)
Weeks 5–8 200 mcg 12 units (0.12 mL)
Weeks 9–12 200 mcg 12 units (0.12 mL)
Weeks 13–16 200 mcg 12 units (0.12 mL)

Frequency: Inject once daily subcutaneously. This once-daily schedule balances efficacy with receptor recovery time, avoiding the rapid attenuation seen with frequent dosing[3]. Administering in the evening may capitalize on nocturnal GH rhythms. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl or roll until completely dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

For Standard 10–20 Day Cycle

  • Peptide Vials (GHRP-2, 5 mg each):
    • 8 weeks ≈ 2 vials
    • 12 weeks ≈ 4 vials
    • 16 weeks ≈ 5 vials
  • Insulin Syringes (U-100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
    • 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
    • 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Stimulate endogenous growth hormone secretion through ghrelin receptor activation[1].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 100–300 mcg daily with gradual titration; higher doses show dose-dependent responses but may offer limited added benefit with routine use[4].
  • Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated (use within 2–3 weeks for optimal integrity).

Dosing Protocol

Suggested daily titration approach.

  • Start: 100 mcg daily (Weeks 1–2); this starting dose provides strong GH pulse while allowing tolerance assessment.
  • Mid-level: 150 mcg daily (Weeks 3–4) to enhance GH response if well tolerated.
  • Target: 200 mcg daily (Weeks 5–16) for maximal effect in most research scenarios; advanced researchers may optionally increase to 250–300 mcg.
  • Frequency: Once per day (subcutaneous); evening administration may align with nocturnal GH rhythms.
  • Cycle Length: 8–16 weeks; some attenuation may occur in first 1–2 weeks but response stabilizes with continued dosing[3].

Storage Instructions

Proper storage preserves peptide potency.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; powder is stable at room temperature for short periods but freezer storage maximizes shelf life[8].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–3 weeks for optimal integrity[9]. For longer storage, consider aliquoting and freezing at −20 °C (−4 °F) with carrier protein; avoid repeated freeze–thaw cycles.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Always protect from light and heat.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipodystrophy[13].
  • Very frequent dosing (e.g., every 2 hours) can cause progressive attenuation due to acute tachyphylaxis[3]; once-daily administration avoids this issue.
  • Multiple daily injections (2–3×) have been explored but require strict adherence and may offer limited added benefit[5][6].
  • Document daily dose and site rotation to maintain consistency.

How This Works

GHRP-2 is a synthetic growth hormone secretagogue that binds to and activates ghrelin (GH secretagogue) receptors[1]. This activation triggers potent, pulsatile release of growth hormone from the pituitary gland in a dose-dependent manner[4]. Clinical studies in GH-deficient children demonstrated meaningful GH increases even at low doses (0.3–3.0 mcg/kg), with escalating doses over several months showing sustained efficacy[2]. In healthy adults, doses of 100 mcg SC daily produce acute GH stimulation[3], while routine protocols typically maintain 100–300 mcg/day to balance efficacy with receptor sensitivity. The peptide has been well tolerated in clinical trials with no significant adverse effects or toxicity reported at these dosage ranges[2][7].

Potential Benefits & Side Effects

Observations from clinical and preclinical literature.

  • Stimulates robust pulsatile GH release that may support favorable body composition changes and metabolic effects[1][2].
  • In combination therapies (e.g., with GHRH analogs), can significantly increase IGF-1 levels when administered with perfect compliance[5][6].
  • Generally well tolerated with placebo-like safety profile; transient side effects may include mild hunger sensation or flushing[7].
  • Long-term therapy (8–24 months in GH-deficient subjects) has maintained positive effects on growth velocity with careful monitoring[2].
  • Occasional mild injection-site reactions (redness, irritation) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Maintain adequate protein intake and balanced nutrition to support the anabolic effects of elevated GH.
  • Combine with resistance training to maximize body composition benefits.
  • Prioritize sleep quality, as GH pulses naturally occur during deep sleep; evening administration may complement this rhythm.
  • Manage stress effectively to support consistent adherence and recovery.
  • Stay well hydrated to support metabolic processes.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[11][12].

  • Clean the vial rubber stopper and skin with alcohol swabs; allow to dry completely.
  • Use a fine insulin syringe (typically 29–31 gauge, 0.5-inch needle).
  • Pinch an inch of skin fat (abdomen, thigh, or outer upper arm); insert needle at 45° to 90° into subcutaneous tissue[11][12]. (Use 90° angle if ample fatty tissue; 45° for leaner individuals to avoid intramuscular injection.)
  • Do not aspirate for subcutaneous injections—aspiration is unnecessary and can cause needless tissue trauma[11][12].
  • Inject slowly and steadily; wait a few seconds before withdrawing needle at same angle.
  • Apply gentle pressure with swab if needed; do not massage or rub injection site.
  • Rotate sites systematically to prevent irritation and lipodystrophy—space injections at least 1 inch apart[13].

Recommended Source

We recommend Prime Lab Peptides for high-purity GHRP-2 (5 mg).

Why Prime Lab Peptides?

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • Domest Anim Endocrinol
    — Effects of GHRP-2 on GH release and growth performance in swine (mechanism and receptor activation)

  • J Clin Endocrinol Metab
    — Effects of eight months treatment with graded doses of GHRP-2 in GH-deficient children

  • Eur J Endocrinol
    — Five-day treatment with daily subcutaneous GHRP-2: response attenuation and IGF-I effects in healthy young men

  • Endocrine
    — GH/IGF-1 response to acute and chronic GHRP-2, GHRH 1-44, and their combination in older adults

  • Am J Men’s Health
    — Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels

  • Sex Med Rev (PMC)
    — The safety and efficacy of growth hormone secretagogues: comprehensive review

  • Genaxxon Bioscience
    — Product Information: Growth Hormone-Releasing Peptide-2 (GHRP-2), technical specifications

  • Genaxxon Bioscience
    — Storage and stability guidelines for research peptides (lyophilized storage recommendations)

  • Genaxxon Bioscience
    — Reconstituted peptide storage: refrigeration and stability considerations

  • Nurseslabs
    — Subcutaneous administration technique: comprehensive nursing guide

  • Medicine LibreTexts (BCcampus)
    — Intradermal and subcutaneous injections: clinical procedures for safer patient care

  • Chartwell Pennsylvania
    — Administering medication via subcutaneous injection: patient teaching guide

  • Medicine LibreTexts (BCcampus)
    — Site rotation and lipodystrophy prevention in subcutaneous injections